NCT05404711View on ClinicalTrials.gov

Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

November 21, 2023

Study Completion Date

December 14, 2023

Conditions
Overweight and ObesityPreDiabetesInsulin Resistance
Interventions
DEVICE

CGM

Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.

Trial Locations (1)

15224

Children's Hospital of Pittsburgh, Pittsburgh

All Listed Sponsors
lead

Mary Ellen Vajravelu, MD

OTHER

NCT05404711 - Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation | Biotech Hunter | Biotech Hunter